Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：78
|
作者：
Kowanetz, Marcin [1 ]
Zou, Wei [1 ]
Shames, David [1 ]
Cummings, Craig [1 ]
Rizvi, Naiyer [2 ]
Spira, Alexander [3 ,4 ]
Frampton, Garrett [5 ]
Leveque, Vincent [1 ]
Flynn, Susan [1 ]
Mocci, Simonetta [1 ]
Shankar, Geetha [1 ]
Funke, Roel [1 ]
Ballinger, Marcus [1 ]
Waterkamp, Daniel [1 ]
Chen, Daniel [1 ]
Sandler, Alan [1 ]
Hampton, Garret [1 ]
Amler, Lukas [1 ]
Hegde, Priti [1 ]
Hellmann, Matthew [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Columbia Univ, New York, NY USA
[3] US Oncol Res, The Woodlands, TX USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Fdn Med, Cambridge, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Immunotherapy; mutational load; NSCLC; Biomarkers;
D O I：
10.1016/j.jtho.2016.11.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA20.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [1] Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+NSCLC patients
    Griesinger, F.
    Kowanetz, M.
    Zou, W.
    Shames, D. S.
    Cummings, C. A.
    Rizvi, N. A.
    Spira, A.
    Frampton, G.
    Leveque, V.
    Flynn, S.
    Mocci, S.
    Shankar, G.
    Funke, R.
    Ballinger, M.
    Waterkamp, D.
    Chen, D. S.
    Sandler, A.
    Hampton, G.
    Amler, L. C.
    Hedge, P.
    Hellmann, M. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 220 - +
  • [2] Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+NSCLC (POPLAR and OAK)
    Gandara, D. R.
    Kowanetz, M.
    Mok, T. S. K.
    Rittmeyer, A.
    Fehrenbacher, L.
    Fabrizio, D.
    Otto, G.
    Malboeuf, C.
    Lieber, D.
    Paul, S. M.
    Amler, L.
    Riehl, T.
    Schleifman, E.
    Cummings, C. A.
    Hegde, P. S.
    Zou, W.
    Sandler, A.
    Ballinger, M.
    Shames, D. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
    Higgs, B. W.
    Morehouse, C. A.
    Brohawn, P. Z.
    Sridhar, S.
    Raja, R.
    Gao, G.
    Englert, J.
    Ranade, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
    Kowanetz, M.
    Zou, W.
    Shames, D. S.
    Cummings, C.
    Rizvi, N.
    Spira, A. I.
    Frampton, G. M.
    Leveque, V.
    Flynn, S.
    Mocci, S.
    Shankar, G.
    Funke, R.
    Ballinger, M.
    Waterkamp, D.
    Sandler, A.
    Hampton, G.
    Amler, L.
    Hegde, P. S.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFRmutated Advanced NSCLC
    Valdiviezo, N.
    Gray, J. E.
    Janne, P. A.
    Kobayashi, K.
    Yang, J. C. -H.
    Cheng, Y.
    Lee, C. K.
    Sugawara, S.
    Yu, Y.
    Kim, T. M.
    Taggart, S.
    Albayaty, M.
    Ghiorghui, D.
    Planchard, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S102 - S102
  • [6] A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.
    Ricciuti, Biagio
    Arbour, Kathryn C.
    Mahadevan, Navin R.
    Alessi, Joao V.
    Lindsay, James
    Umeton, Renato
    Sinha, Rileen
    Hoojghan, Amir
    Vokes, Natalie
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Polio, Andrew
    Rizvi, Hira
    Leonardi, Giulia
    Plodkowski, Andrew J.
    Felt, Kristen
    Sharma, Bijaya
    Tolstorukov, Michael Y.
    Janne, Pasi A.
    Van Allen, Eliezer M.
    Sholl, Lynette M.
    Rodig, Scott J.
    Hellmann, Matthew D.
    Awad, Mark M.
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Barriers to tumor mutation burden (TMB) testing in NSCLC patients in the US and EU.
    Angel, William H.
    Edathanal, Ciny
    Krishnam, Mahaletchumy
    De Richter, Pieter
    Levent, Ayse
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] EXAMINING ELEVATED TMB AND CLINICAL BENEFIT OF 1L IMMUNE CHECKPOINT INHIBITOR IN ADVANCED NSCLC
    Carbone, David
    Sands, Jacob
    Li, Gerald
    Schrock, Alexa
    Graf, Ryon
    Zhang, Liangliang
    Murugesan, Karthikeyan
    Ross, Jeffrey
    Tolba, Khaled
    Oxnard, Geoffrey
    Huang, Richard
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A64 - A64
  • [9] Atezolizumab for PD-L1-Selected Patients with NSCLC
    Horita, Nobuyuki
    Fukuda, Nobuhiko
    Kaneko, Takeshi
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (06): : 583 - 584
  • [10] Long-Term Survival in Atezolizumab-Treated Patients with 2L+NSCLC from Ph III Randomized OAK Study
    Satouchi, M.
    Fehrenbacher, L.
    Dols, M. Cobo
    Han, J.
    Von Pawel, J.
    Bordoni, R.
    Hida, T.
    Park, K.
    Moro-Sibilot, D.
    Conkling, P.
    Matheny, C.
    Yu, W.
    He, P.
    Kowanetz, M.
    Gandhi, M.
    Ballinger, M.
    Sandler, A.
    Gandara, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1794 - S1794
12345